Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 6 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Semaglutide may reduce cardiovascular events in non-diabetic patients.
Last updated July 6, 2026
Key finding
The primary end point of first major adverse cardiovascular event (MACE) was reduced by 20% with semaglutide versus placebo.
The study evaluated the effects of semaglutide on cardiovascular events in individuals with overweight or obesity and established cardiovascular disease without diabetes, finding a 20% reduction in major adverse cardiovascular events.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the effects of semaglutide on cardiovascular events in individuals with overweight or obesity and established cardiovascular disease without diabetes, finding a 20% reduction in major adverse cardiovascular events.
Clinical relevance
The findings are clinically significant as they suggest that semaglutide can be an effective intervention for reducing cardiovascular risks in a high-risk population. Given the increasing prevalence of obesity and related cardiovascular diseases, this treatment could help improve patient outcomes and reduce healthcare costs associated with cardiovascular events.
Keep in mind
The study's population may not be generalizable to all individuals with cardiovascular disease. Long-term effects of semaglutide on cardiovascular outcomes remain unclear. The trial did not include participants with diabetes, limiting applicability.
Published in
Journal Reference
Publication details and source links for this paper.
Ildiko L, John D, Steven EK, et al. Semaglutide Reduces Cardiovascular Events in Individuals with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes. Diabetes Care. 2024;47(8):1360-1369. doi:10.2337/dc24-0764
Main Effects
Semaglutide reduced the first major adverse cardiovascular event (MACE) by 20% compared to placebo.
Cardiovascular mortality risk reduction was consistent across baseline HbA1c groups.
Other cardiovascular outcomes, including nonfatal myocardial infarction and stroke, showed consistent trends across HbA1c subgroups.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and All-cause mortality, Cardiovascular events, Cardiovascular mortality, and 8 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- All-cause mortality
- Cardiovascular events
- Cardiovascular mortality
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
11
Evidence pairs
11
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
11
Evidence pairs
109
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 11 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Related evidence
Evidence topic
Cardiovascular Risk
Save evidence
Evidence topic
GLP-1 Receptor Agonists
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerCardiovascular mortality
Semaglutide → Cardiovascular mortality
Semaglutide → Cardiovascular mortality
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 86
- Very Positive
- ConsistencyScore™
- 71
- generally_consistent
Supporting studies: Based on 7 studies
Add to Evidence TrackerComposite of CV death, non-fatal myocardial infarction, or non-fatal stroke
Semaglutide → Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke
Semaglutide → Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerCoronary revascularization
Semaglutide → Coronary revascularization
Semaglutide → Coronary revascularization
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerHeart failure hospitalizations
Semaglutide → Heart failure hospitalizations
Semaglutide → Heart failure hospitalizations
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerHospitalization for unstable angina
Semaglutide → Hospitalization for unstable angina
Semaglutide → Hospitalization for unstable angina
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 38
- Slightly Negative
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 4 studies
Add to Evidence TrackerUrgent medical visit for heart failure
Semaglutide → Urgent medical visit for heart failure
Semaglutide → Urgent medical visit for heart failure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Semaglutide showed a 20% decrease in major cardiovascular events.
- No significant difference in cardiovascular mortality across HbA1c groups.
- Consistent cardiovascular outcomes across various subgroups.
Who this applies to
- Adults with overweight or obesity.
- Individuals with established cardiovascular disease without diabetes.
Keep in Mind
- Results may not apply to individuals with diabetes.
- The study focused on a specific population, limiting broader applicability.
- Further research is needed to confirm long-term effects.
Between the Lines
- The study's population may not be generalizable to all individuals with cardiovascular disease.
- Long-term effects of semaglutide on cardiovascular outcomes remain unclear.
- The trial did not include participants with diabetes, limiting applicability.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 86
- Very Positive
- ConsistencyScore™
- 71
- generally_consistent
Supporting studies: Based on 7 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 6 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
7 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
7 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Intervention: SemaglutideOutcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
7 results
All studies on Semaglutide and All-cause mortality
Intervention: SemaglutideOutcome: All-cause mortality
6 results
All studies on Semaglutide
Intervention: Semaglutide
7 results
All studies measuring Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Outcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
7 results
All studies measuring All-cause mortality
Outcome: All-cause mortality
6 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 1 study
- 2
All-cause mortality
EvidenceScore™ Strong | EvidenceScore™ 82.9 | weak positive | ConsistencyScore™ Mixed | 1 study
- 3
Cardiovascular events
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Semaglutide improve coronary revascularization?
Emerging Evidence
Current evidence does not show a clear benefit of Semaglutide for Coronary revascularization.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Coronary revascularization
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Semaglutide improve heart failure composite?
Emerging Evidence
Current evidence does not show a clear benefit of Semaglutide for Heart failure composite.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Heart failure composite
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Semaglutide improve heart failure hospitalizations?
Emerging Evidence
Current evidence does not show a clear benefit of Semaglutide for Heart failure hospitalizations.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Heart failure hospitalizations
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.Semaglutide improves vascular and liver function in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.